Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

NRX-101 outperforms lurasidone
February 2019
SHARING OPTIONS:

WILMINGTON, Del.—NeuroRx recently shared data from its Phase 2 STABIL-B study of NRX-101 vs. lurasidone in patients with severe bipolar depression and acute suicidal ideation and behavior (ASIB), which was also presented at the American Congress of Neuropsychopharmacology. The study showed a statistically significant 11-point difference on the Montgomery Åsberg Depression Rating Scale (MADRS) between NRX-101 and lurasidone groups at day 14, and patients who received NRX-101 maintained a lower depression score over the six weeks of the trial vs. patients on lurasidone. None of the NRX-101 patients relapsed, though two of the five lurasidone patients did. NRX-101 was well tolerated overall, with no serious adverse events or discontinuations, and demonstrated no evidence of abuse liability. NeuroRx is currently initiating a pivotal Phase 2b/3 study of NRX-101.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.